Ani Pharmaceuticals (ANIP) Total Debt (2012 - 2026)

Ani Pharmaceuticals (ANIP) has 15 years of Total Debt data on file, last reported at $305.3 million in Q1 2026.

• For the quarter ending Q1 2026, Total Debt fell 3.54% year-over-year to $305.3 million; the trailing twelve-month figure through Mar 2026 stood at $305.3 million (down 3.54% YoY), and the FY2025 full-year result was $309.1 million, down 2.88% from the prior year.
• Total Debt declined to $305.3 million in Q1 2026, from $309.1 million in the prior quarter.
• In the past five years, Total Debt ranged from a high of $318.3 million in Q4 2024 to a low of $285.0 million in Q1 2024.
• A 5-year average of $297.1 million and a median of $287.2 million in 2022 frame the typical range for Total Debt.
• Across the five-year window, Total Debt surged 56.55% in 2022 and dropped 3.54% in 2026, its largest moves.
• Tracing ANIP's Total Debt over 5 years: stood at $285.7 million in 2022, then rose by 4.0% to $297.1 million in 2023, then advanced by 7.13% to $318.3 million in 2024, then dropped by 2.88% to $309.1 million in 2025, then declined by 1.23% to $305.3 million in 2026.
• Business Quant data shows ANIP's Total Debt at $305.3 million in Q1 2026, $309.1 million in Q4 2025, and $312.9 million in Q3 2025.